Last reviewed · How we verify
NCT06384911
InvesT1D: Promoting Adolescent Investment in Diabetes Care
NA trial testing Financial Incentives Program in Type 1 Diabetes in 96 participants. Currently enrolling.
31 July 2027
Quick facts
| Lead sponsor | Harvard Pilgrim Health Care |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 96 |
| Start date | 25 June 2024 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 October 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Financial Incentives Program
Conditions studied
- Type 1 Diabetes — all drugs for Type 1 Diabetes →
Sponsor
Harvard Pilgrim Health Care — full company profile →
Who can join
12 and older, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management and clinical outcomes goals during the study. Researchers will compare changes in glucose levels, as well as adolescent and caregiver person-reported outcomes between groups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06384911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 1 Diabetes
Currently open trials in the same condition.
- NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
- NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
- NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
- NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
- NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting
Other Harvard Pilgrim Health Care trials
Trials by the same sponsor.
- NCT06516627 — Front-of-Package Nutrition Labels · NA · completed
- NCT06584539 — Eco-labels on Restaurant Menus · NA · completed
- NCT05423756 — INSPIRE Trial for Skin and Soft Tissue Infections · NA · completed
- NCT05423743 — INSPIRE Trial for Abdominal Infections · NA · completed
- NCT05281744 — Collaborative Care Coordination Program for Alzheimer's Disease and Related Dementias · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06384911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Harvard Pilgrim Health Care
- Last refreshed: 16 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06384911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing